FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043915025> ?p ?o ?g. }

• W2043915025 endingPage "187" @default.
• W2043915025 startingPage "178" @default.
• W2043915025 abstract "Background DNA aptamers represent a novel strategy in anti-cancer medicine. AS1411, a DNA aptamer targeting nucleolin (a protein which is overexpressed in many tumor types), was evaluated in patients with metastatic, clear-cell, renal cell carcinoma (RCC) who had failed treatment with ≥1 prior tyrosine kinase inhibitor. Methods In this phase II, single-arm study, AS1411 was administered at 40 mg/kg/day by continuous intravenous infusion on days 1–4 of a 28-day cycle, for two cycles. Primary endpoint was overall response rate; progression-free survival (PFS) and safety were secondary endpoints. Results 35 patients were enrolled and treated. One patient (2.9 %) had a response to treatment. The response was dramatic (84 % reduction in tumor burden by RECIST 1.0 criteria) and durable (patient remains free of progression 2 years after completing therapy). Whole exome sequencing of this patient’s tumor revealed missense mutations in the mTOR and FGFR2 genes which is of interest because nucleolin is known to upregulate mTOR pathway activity by enhancing AKT1 mRNA translation. No other responses were seen. Thirty-four percent of patients had an AS1411-related adverse event, all of which were mild or moderate. Conclusions AS1411 appears to have minimal activity in unselected patients with metastatic RCC. However, rare, dramatic and durable responses can be observed and toxicity is low. One patient in this study had an excellent response and was found to have FGFR2 and mTOR mutations which will be of interest in future efforts to discover and validate predictive biomarkers of response to nucleolin targeted compounds. DNA aptamers represent a novel way to target cancer cells at a molecular level and continue to be developed with a view to improving treatment and imaging in cancer medicine." @default.
• W2043915025 created "2016-06-24" @default.
• W2043915025 creator A5007177878 @default.
• W2043915025 creator A5039044023 @default.
• W2043915025 creator A5050435057 @default.
• W2043915025 creator A5050649350 @default.
• W2043915025 creator A5052504518 @default.
• W2043915025 creator A5055048393 @default.
• W2043915025 creator A5066372195 @default.
• W2043915025 creator A5068685482 @default.
• W2043915025 creator A5068721624 @default.
• W2043915025 creator A5072806624 @default.
• W2043915025 creator A5075799959 @default.
• W2043915025 creator A5078550448 @default.
• W2043915025 creator A5087213703 @default.
• W2043915025 date "2013-11-16" @default.
• W2043915025 modified "2023-10-12" @default.
• W2043915025 title "A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma" @default.
• W2043915025 cites W1999966467 @default.
• W2043915025 cites W2002619034 @default.
• W2043915025 cites W2013566223 @default.
• W2043915025 cites W2018216617 @default.
• W2043915025 cites W2037991649 @default.
• W2043915025 cites W2039483976 @default.
• W2043915025 cites W2041919391 @default.
• W2043915025 cites W2044824066 @default.
• W2043915025 cites W2086113348 @default.
• W2043915025 cites W2098475024 @default.
• W2043915025 cites W2099088585 @default.
• W2043915025 cites W2100669312 @default.
• W2043915025 cites W2104830962 @default.
• W2043915025 cites W2105023720 @default.
• W2043915025 cites W2115875921 @default.
• W2043915025 cites W2118398430 @default.
• W2043915025 cites W2128542677 @default.
• W2043915025 cites W2138601221 @default.
• W2043915025 cites W2139248078 @default.
• W2043915025 cites W2149456801 @default.
• W2043915025 cites W2153867442 @default.
• W2043915025 cites W2165948908 @default.
• W2043915025 cites W2335012284 @default.
• W2043915025 cites W2556094713 @default.
• W2043915025 doi "https://doi.org/10.1007/s10637-013-0045-6" @default.
• W2043915025 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4560460" @default.
• W2043915025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24242861" @default.
• W2043915025 hasPublicationYear "2013" @default.
• W2043915025 type Work @default.
• W2043915025 sameAs 2043915025 @default.
• W2043915025 citedByCount "289" @default.
• W2043915025 countsByYear W20439150252013 @default.
• W2043915025 countsByYear W20439150252014 @default.
• W2043915025 countsByYear W20439150252015 @default.
• W2043915025 countsByYear W20439150252016 @default.
• W2043915025 countsByYear W20439150252017 @default.
• W2043915025 countsByYear W20439150252018 @default.
• W2043915025 countsByYear W20439150252019 @default.
• W2043915025 countsByYear W20439150252020 @default.
• W2043915025 countsByYear W20439150252021 @default.
• W2043915025 countsByYear W20439150252022 @default.
• W2043915025 countsByYear W20439150252023 @default.
• W2043915025 crossrefType "journal-article" @default.
• W2043915025 hasAuthorship W2043915025A5007177878 @default.
• W2043915025 hasAuthorship W2043915025A5039044023 @default.
• W2043915025 hasAuthorship W2043915025A5050435057 @default.
• W2043915025 hasAuthorship W2043915025A5050649350 @default.
• W2043915025 hasAuthorship W2043915025A5052504518 @default.
• W2043915025 hasAuthorship W2043915025A5055048393 @default.
• W2043915025 hasAuthorship W2043915025A5066372195 @default.
• W2043915025 hasAuthorship W2043915025A5068685482 @default.
• W2043915025 hasAuthorship W2043915025A5068721624 @default.
• W2043915025 hasAuthorship W2043915025A5072806624 @default.
• W2043915025 hasAuthorship W2043915025A5075799959 @default.
• W2043915025 hasAuthorship W2043915025A5078550448 @default.
• W2043915025 hasAuthorship W2043915025A5087213703 @default.
• W2043915025 hasBestOaLocation W20439150252 @default.
• W2043915025 hasConcept C118552586 @default.
• W2043915025 hasConcept C121608353 @default.
• W2043915025 hasConcept C126322002 @default.
• W2043915025 hasConcept C143998085 @default.
• W2043915025 hasConcept C183873130 @default.
• W2043915025 hasConcept C203092338 @default.
• W2043915025 hasConcept C2776525860 @default.
• W2043915025 hasConcept C2777472916 @default.
• W2043915025 hasConcept C2779699572 @default.
• W2043915025 hasConcept C2780723820 @default.
• W2043915025 hasConcept C2781230642 @default.
• W2043915025 hasConcept C502942594 @default.
• W2043915025 hasConcept C535046627 @default.
• W2043915025 hasConcept C55493867 @default.
• W2043915025 hasConcept C62478195 @default.
• W2043915025 hasConcept C71924100 @default.
• W2043915025 hasConcept C86554907 @default.
• W2043915025 hasConcept C86803240 @default.
• W2043915025 hasConceptScore W2043915025C118552586 @default.
• W2043915025 hasConceptScore W2043915025C121608353 @default.
• W2043915025 hasConceptScore W2043915025C126322002 @default.
• W2043915025 hasConceptScore W2043915025C143998085 @default.
• W2043915025 hasConceptScore W2043915025C183873130 @default.

• next